Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1968 2
1970 1
1972 1
1974 1
1975 2
1976 2
1977 5
1978 7
1979 8
1980 7
1981 3
1982 6
1983 6
1984 8
1985 4
1986 17
1987 14
1988 10
1989 11
1990 9
1991 9
1992 10
1993 7
1994 6
1995 7
1996 6
1997 15
1998 9
1999 15
2000 6
2001 8
2002 7
2003 15
2004 9
2005 14
2006 10
2007 14
2008 8
2009 15
2010 18
2011 14
2012 14
2013 13
2014 13
2015 21
2016 11
2017 8
2018 19
2019 18
2020 36
2021 23
2022 33
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

528 results
Results by year
Filters applied: . Clear all
Page 1
Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.
Ohmori T, Yamaoka T, Ando K, Kusumoto S, Kishino Y, Manabe R, Sagara H. Ohmori T, et al. Among authors: kusumoto s. Int J Mol Sci. 2021 Jan 14;22(2):792. doi: 10.3390/ijms22020792. Int J Mol Sci. 2021. PMID: 33466795 Free PMC article. Review.
Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T, Kusumoto S, Ando K, Ohba M, Ohmori T. Yamaoka T, et al. Among authors: kusumoto s. Int J Mol Sci. 2018 Nov 6;19(11):3491. doi: 10.3390/ijms19113491. Int J Mol Sci. 2018. PMID: 30404198 Free PMC article. Review.
Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis.
Ando K, Manabe R, Kishino Y, Kusumoto S, Yamaoka T, Tanaka A, Ohmori T, Sagara H. Ando K, et al. Among authors: kusumoto s. Cancers (Basel). 2021 Jul 23;13(15):3704. doi: 10.3390/cancers13153704. Cancers (Basel). 2021. PMID: 34359604 Free PMC article. Review.
Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.
Shimada K, Yoshida K, Suzuki Y, Iriyama C, Inoue Y, Sanada M, Kataoka K, Yuge M, Takagi Y, Kusumoto S, Masaki Y, Ito T, Inagaki Y, Okamoto A, Kuwatsuka Y, Nakatochi M, Shimada S, Miyoshi H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Shiozawa Y, Nannya Y, Okabe A, Kohno K, Atsuta Y, Ohshima K, Nakamura S, Ogawa S, Tomita A, Kiyoi H. Shimada K, et al. Among authors: kusumoto s. Blood. 2021 Mar 18;137(11):1491-1502. doi: 10.1182/blood.2020007245. Blood. 2021. PMID: 33512416 Free PMC article.
An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma.
Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T, Rai S, Katsuya H, Ishikawa J, Yamada H, Kato K, Tachibana M, Kakurai Y, Adachi N, Tobinai K, Yonekura K, Ishitsuka K. Izutsu K, et al. Among authors: kusumoto s. Blood. 2022 Sep 23:blood.2022016862. doi: 10.1182/blood.2022016862. Online ahead of print. Blood. 2022. PMID: 36150143 Free article.
Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: Phase IIb results.
Utsunomiya A, Izutsu K, Jo T, Yoshida S, Tsukasaki K, Ando K, Choi I, Imaizumi Y, Kato K, Kurosawa M, Kusumoto S, Miyagi T, Ohtsuka E, Sasaki O, Shibayama H, Shimoda K, Takamatsu Y, Takano K, Yonekura K, Makita S, Taguchi J, Gillings M, Onogi H, Tobinai K. Utsunomiya A, et al. Among authors: kusumoto s. Cancer Sci. 2022 Aug;113(8):2778-2787. doi: 10.1111/cas.15431. Epub 2022 Jun 7. Cancer Sci. 2022. PMID: 35579212 Free PMC article.
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial.
Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto M, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Izumi T, Kin Y, Tsukasaki K, Hashimoto D, Yuge M, Yanagisawa A, Kuwatsuka Y, Shimada S, Masaki Y, Niitsu N, Kiyoi H, Suzuki R, Tokunaga T, Nakamura S, Kinoshita T. Shimada K, et al. Among authors: kusumoto s. Lancet Oncol. 2020 Apr;21(4):593-602. doi: 10.1016/S1470-2045(20)30059-0. Epub 2020 Mar 11. Lancet Oncol. 2020. PMID: 32171071 Clinical Trial.
Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Ando K, Manabe R, Kishino Y, Kusumoto S, Yamaoka T, Tanaka A, Ohmori T, Ohnishi T, Sagara H. Ando K, et al. Among authors: kusumoto s. Curr Oncol. 2021 Feb 27;28(2):1094-1113. doi: 10.3390/curroncol28020106. Curr Oncol. 2021. PMID: 33673470 Free PMC article. Review.
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Kusumoto S, et al. Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19. Blood. 2019. PMID: 30341058 Free PMC article. Clinical Trial.
528 results